OPKO Health, Inc. (NYSE Amex: OPK) today announced that it has completed
the acquisition of Pharmacos Exakta, S.A. de C.V. (“Pharmacos Exakta”),
a privately-owned Mexican pharmaceutical company engaged in the
manufacture, marketing and distribution of ophthalmic and other
pharmaceutical products for government and private markets since 1957.
OPKO acquired Pharmacos Exakta, including a manufacturing facility owned
by an affiliate, for cash and shares of OPKO Common Stock.
Phillip Frost, OPKO’s Chairman and Chief Executive Officer, commented,
“We believe this acquisition will provide OPKO with an excellent
platform to expand manufacturing and distribution capabilities for a
wide range of products while, at the same time, maintaining our original
interest in ophthalmology. It also furthers our strategy of expanding
commercial activities while we continue to develop our important
diagnostic and therapeutic products, as well as our flu vaccine.”